More Data on Pregnancy Outcomes Associated with Lithium Use During Pregnancy
Lithium use during pregnancy was associated with an increased risk of preterm birth and large for gestational age infants.
Zuranolone Improves Anxiety Symptoms and Insomnia in Women with Postpartum Depression
In women with postpartum depression, zuranolone was associated with concurrent improvements in depression, anxiety symptoms, and insomnia beginning at day 3.
Depression, Anxiety During Pregnancy Associated with Significant Increase in Adverse Perinatal Outcomes
Diagnosis of a mood or anxiety disorder during pregnancy was associated with a 3.5-fold increase in adverse perinatal outcomes.
Long-term behavioral follow-up of children exposed to mood stabilizers and antidepressants: A look forward – ObGynNews
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on the long-term behavioral follow-up of children exposed to mood stabilizers and antidepressants with Ob.Gyn News on August 16,
Still Not Enough Data on the Reproductive Safety of Oxcarbazepine (Trileptal)
This meta-analysis is reassuring regarding risk for malformations in children exposed prenatally to oxcarbazepine; however, we still need more data to fully assess reproductive safety.
Zuranolone: Novel, Rapid-Acting Antidepressant Awaits FDA Approval
A New Drug Application for zuranolone awaits FDA approval for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Prenatal Exposure to Topiramate (Topamax):Â Impact on Neurodevelopmental Outcomes
Data from a Nordic register-based study observed a significant increase in risk for autism spectrum disorder and intellectual disability in children with prenatal exposure to topiramate.
Increased Risk of Preterm Birth in Veterans with PTSD
Largest studies to date demonstrate statistically significant risk of preterm birth among women with active PTSD.
Should Valproic Acid Be Used in Women of Reproductive Age? Experts Disagree
The use of valproic acid during pregnancy is associated with a significant increase in risk of major malformations and neurodevelopmental disorders. Given these risks, should it be a treatment option for women of childbearing age?
Weekly Roundup for OCTOBER 21, 2022: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.